Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3

To Host Conference Call and Webcast Today at 4:30 p.m. ET

LOS ANGELES, May 13, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced its financial results for the first quarter 2019 and provided a corporate update.

“We continue with the clinical development of CAP-1002, our lead cell therapy product, to treat Duchenne muscular dystrophy,” said Linda Marbán, Ph.D., Capricor president and chief executive officer. Our HOPE-2 clinical trial, which is testing the safety and efficacy of CAP-1002 in boys and young men in the advanced stages of Duchenne, has enrolled 20 patients to date.  Previous pre-clinical and clinical studies have shown that CAP-1002 is generally safe, well-tolerated and demonstrated significant and sustained signals of improvement in cardiac and skeletal muscle function in patients with Duchenne muscular dystrophy. We will be conducting an interim analysis in early Q3 and look forward to sharing that data with the patient and investor community.”

Capricor has been granted RMAT and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CAP-1002 for the treatment of Duchenne muscular dystrophy.

CAP-2003 is comprised of proprietary extracellular vesicles, including exosomes, which are derived from cardiosphere-derived cells. Exosomes are nano-sized, membrane-enclosed vesicles, that are secreted by cells and contain bioactive molecules, including proteins, RNAs and microRNAs. Exosomes act as messengers to regulate the functions of neighboring cells. Because of these unique capacities, researchers are increasingly viewing exosomes as both a potential therapeutic and a vehicle to deliver gene and other therapies to targeted tissues in the human body.

“We continue to be encouraged by exciting developments in the exosomes field and we continue to explore their use as a potential therapeutic and as a delivery vehicle for genes and other drugs to targeted tissues,” said Dr. Marbán.

First Quarter Highlights and Recent Clinical and Operational Developments

  • The Company resumed dosing of patients already enrolled in the HOPE-2 clinical trial of CAP-1002 in accordance with the study protocol. It is the Company’s intention to conduct an interim analysis on available data in early Q3 2019. The HOPE-2 study is a Phase II, randomized, double-blind, placebo-controlled study in patients in the later stages of Duchenne muscular dystrophy, a fatal genetic disease with few treatment options. HOPE-2 will evaluate the safety and efficacy of repeat doses of CAP-1002, which consists of allogeneic cardiosphere-derived cells, or CDCs. CAP-1002 has been shown to exert potent immunomodulatory activity and stimulate cellular regrowth. Enrollment of new patients will depend on various factors but will not commence until additional funding is secured.
  • The Journal of Neurology published the results of the HOPE-Duchenne clinical trial reporting significant improvements in Duchenne muscular dystrophy patients treated with Capricor’s CAP-1002. The Phase I/II, randomized, controlled, open-label trial found that CAP-1002 demonstrated improvement in cardiac muscle function and reduction in cardiac scarring that were statistically-significant and sustained improvement of skeletal muscle functions in patients with Duchenne muscular dystrophy. The HOPE-Duchenne trial also found no serious safety issues, according to the study published in the January 23, 2019, online issue of Neurology, the medical journal of the American Academy of Neurology.

Anticipated Events and Milestones in 2019

  • Plan to report interim data from the HOPE-2 clinical trial in early Q3 2019.
  • Continue to conduct pre-clinical research for CAP-2003 to treat various diseases of inflammation and fibrosis.
  • Continue to explore financing and other strategic alternatives with respect to the Company as well as one or more of our product candidates.

First Quarter Financial Results

The Company reported a net loss of approximately $2.5 million, or $0.08 per share, for the first quarter of 2019, compared to a net loss of approximately $3.7 million, or $0.14 per share, for the first quarter of 2018.

As of March 31, 2019, the Company’s cash, cash equivalents and marketable securities totaled approximately $7.2 million compared to approximately $7.3 million on December 31, 2018. Additionally, in the first quarter of 2019, Capricor raised approximately $1.4 million in net proceeds at an average price of approximately $0.66 per share under its at-the-market offering program. The Company’s at-the-market offering program expired on April 23, 2019.

Capricor believes that its current financial resources should be sufficient to fund its operations and meet its financial obligations into the fourth quarter of 2019 based on the Company's current projections.

Conference Call and Webcast

To participate in the conference call, please dial 866-717-4562 (domestic) or 210-874-7812 (international) and reference the access code: 4575759

To participate via a webcast, please visit: The webcast will be archived for approximately 30 days and will be available at

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.  The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine. For more information, visit

Keep up with Capricor on social media:, and

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 29, 2019, and as amended by its Amendment No. 1 to Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on April 1, 2019. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. CAP-2003 has not yet been approved for clinical investigation.


  Three months ended March 31,  
    2019     2018  
Revenue $   230,504   $   400,066  
Research and development     1,811,182       2,696,517  
General and administrative     976,490       1,389,732  
TOTAL OPERATING EXPENSES     2,787,672       4,086,249  
LOSS FROM OPERATIONS     (2,557,168)       (3,686,183)  
Investment income      37,823       14,653  
NET LOSS     (2,519,345)       (3,671,530)  
Net unrealized gain (loss) on marketable securities     (12,393)       8,709  
COMPREHENSIVE LOSS $   (2,531,738)   $   (3,662,821)  
Net loss per share, basic and diluted $   (0.08)   $   (0.14)  
Weighted average number of shares, basic and diluted     32,903,837       26,905,331  


    March 31, 2019
  December 31, 2018  
Cash, cash equivalents and marketable securities   $   7,170,220   $   7,256,416  
Total assets   $   8,617,505   $   9,247,065  
Total liabilities   $   4,877,203   $   4,631,478  
Total stockholders' equity - 33,661,346 and 31,387,729 common shares issued and          
outstanding at March 31, 2019 and December 31, 2018, respectively       3,740,302       4,615,587  
Total liabilities and stockholders' equity   $   8,617,505   $   9,247,065  

For more information, please contact:

AJ Bergmann, Chief Financial Officer


2017 Capricor Final Logo v2@0.5x.png

Source: Capricor Therapeutics, Inc.